In Vivo Assessment of Antileishmanial Property of 4-(4,4,8-Trimethyl-7- oxo-3-oxabicyclo[3.3.1]non-2-yl)-benzoic Acid Methyl Ester, an Oxabicyclo[ 3.3.1]nonanones
Shyam Lal Mudavath,
Anil K. Saikia,
Vikash Kumar Dubey.
The high toxicity and the growing resistance are the major drawbacks of available antileishmanials. Our previous
in vitro studies have identified oxabicyclo[3.3.1]nonanones as antileishmanial agents that act on the redox enzymes of
the parasite. In the current study, antileishmanial activity of 4-(4,4,8-trimethyl-7-oxo-3-oxabicyclo[3.3.1]non-2-yl)-
benzoic acid methyl ester (PS 203) the most potent oxabicyclo[3.3.1]nonanone identified in our previous study is evaluated
using the hamster model. There was 77.29 ± 3.0 % inhibition of parasite growth observed after a 5-day treatment of 5
mg/kg body weight dose. Further, the in vivo toxicity study of the compound in Swiss albino mice revealed no hepatic or
Keywords: Drug design, In vivo assessment, Leishmaniasis, Oxabicyclo[3.3.1]nonanones, Toxicity.
Rights & PermissionsPrintExport